SCHEMBL2354797

SCHEMBL2354797

c1coc(-c2cc(C3CC[N]CC3)[nH]n2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.61
ALDH1A1 P00352 3/20 0.61
PDE10A Q9Y233 1/20 0.51
MKNK1 Q9BUB5 3/20 0.40
MKNK2 Q9HBH9 3/20 0.40
FYN P06241 1/20 0.39
HCAR3 P49019 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALOX15 P16050 2/20 0.38
POLB P06746 2/20 0.38
LMNA P02545 1/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
CASP1 P29466 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27926759 0.91 MAPT (0.67) MAPTALDH1A1PDE10AMKNK1MKNK2
SCHEMBL187658 0.86 MAPT (0.61) MAPTALDH1A1PDE10AMKNK1MKNK2
SCHEMBL14276938 0.77 MAPT (0.61) MAPTALDH1A1PDE10ATDP1KMT2A
SCHEMBL3249350 0.76 DRD4 (0.60) MKNK1MKNK2POLBKMT2AMEN1
SCHEMBL7705423 0.72 HTT (0.64) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL3319800 0.70 MAPT (0.52) MAPTALDH1A1PDE10ATDP1KMT2A
SCHEMBL3319805 0.70 ALDH1A1 (0.54) MAPTALDH1A1PDE10ATDP1KMT2A
SCHEMBL645061 0.68 PDE10A (0.64) MAPTALDH1A1PDE10AKDM4EALOX15
SCHEMBL7914418 0.68 PDE10A (1.00) MAPTALDH1A1PDE10AKDM4EALOX15
SCHEMBL25239199 0.68 ALDH1A1 (0.49) MAPTALDH1A1KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6967216-B2 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor ASTRAZENECA AB (SE) 2005-11-22 US claimed
US-20030225097-A1 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor ASTRAZENECA AB (SE) 2003-12-04 US claimed
EP-2536689-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN Amgen Inc. (US) 2012-12-26 EP disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed
US-6967216-B2 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor ASTRAZENECA AB (SE) 2005-11-22 US disclosed
US-20030225097-A1 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor ASTRAZENECA AB (SE) 2003-12-04 US disclosed
EP-1278739-A1 AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR AstraZeneca AB (SE) 2003-01-29 EP disclosed
WO-2001085714-A1 AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR ASTRAZENECA AB (SE) 2001-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225097-A1 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor NPY5R, NPY1R, NPY2R MAPT 1610/4885ALDH1A1 3792/4885PDE10A 2008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.